Sanitas AB - Notification on material event

Clearance received from the Antimonopoly Committee of Ukraine

Kaunas, Lithuania, 2011-07-11 15:09 CEST (GLOBE NEWSWIRE) -- Reference is made
to the public releases of 24th May 2011 announcing that Valeant Pharmaceuticals
International, Inc. (“Valeant”) intends to acquire the entire 87.2%
shareholding from the funds advised by Citi Venture Capital International
(“CVCI”, through the legal entities Citigroup Venture Capital International
Jersey Limited and Baltic Pharma Limited), AB Invalda (“Invalda”), Amber Trust
II S.C.A. (“Amber”) and certain other persons (together the “Controlling
Shareholders”) and, following such acquisition, to launch a mandatory takeover
offer to acquire the remaining shares in AB Sanitas from the minority
shareholders (more information is available at:
http://www.sanitasgroup.com/index.php/news/news/the-signature-date-of-the-share-
sale-and-purchase-agreement-has-been-corrected/11468)
and 10th June 2011 regarding the submission of the notification about the
proposed transaction to the Antimonopoly Committee of Ukraine (more information
is available at:
http://www.sanitasgroup.com/index.php/news/news/notification-of-the-proposed-tra
nsaction-to-a-competition-authority/11483
). 
Today, 11th July 2011, AB Sanitas announces that Valeant has received a
decision from the Antimonopoly Committee of Ukraine approving Valeant's
intended acquisition without imposing any conditions. 
Clearance from the Competition Council of the Republic of Lithuania and the
Polish Office for Competition and Consumer Protection is still pending. 
A further announcement will be made when appropriate.
This announcement is also available on AB Sanitas' website:
www.sanitasgroup.com. 

A person authorised to provide additional information: Mr. Saulius Jurgelėnas,
Chief Executive Officer of AB Sanitas, phone number +370 686 67779. 




         Lawyer
         Dovile Morkyte
         +370 615 15163